FIELD: medicine.
SUBSTANCE: present invention relates to medicine and pharmaceutics, specifically to use of a compound of formula II or a pharmaceutically acceptable salt thereof, for preparing a drug for treating a disease caused by a virus selected from SARS-CoV-2, influenza virus, Zika virus, bunyavirus and enterovirus.
EFFECT: treating a disease caused by a virus selected from SARS-CoV-2, influenza virus, Zika virus, bunyavirus and enterovirus.
18 cl, 2 dwg, 1 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
5'-O-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE AND ITS APPLICATION | 2022 |
|
RU2791523C1 |
METHOD FOR OBTAINING 5'-O-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE | 2022 |
|
RU2791916C1 |
METHOD FOR PRODUCING PROPHYLACTIC ANTIVIRAL COMPOSITION BASED ON EPIGALLOCATECHIN-3-GALLATE (EGCG) | 2021 |
|
RU2771898C1 |
SARS-CoV-2 CORONAVIRUS REPLICATION INHIBITOR BASED ON HUMIC SUBSTANCES | 2020 |
|
RU2752872C1 |
RECOMBINANT SARS-CoV-2 S PROTEIN RBD-BINDING PROTEIN | 2022 |
|
RU2778942C1 |
SARS-COV-2 REPLICATION INHIBITOR BASED ON A WATER EXTRACT OF THE FUNGUS INONOTUS OBLIQUUS | 2020 |
|
RU2741714C1 |
SARS-COV-2 CORONAVIRUS REPLICATION INHIBITOR BASED ON MELANIN FROM INONOTUS OBLIQUUS FUNGUS | 2020 |
|
RU2747018C1 |
THE STRAIN OF HYBRID CULTURED HOMO SAPIENS/Mus MUSCULUS CELLS Hu-C6D7-RBD IS A PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE RBD DOMAIN S OF THE SARS-CoV-2 VIRUS PROTEIN | 2022 |
|
RU2788359C1 |
INDOLE-3-CARBOXYLIC ACID DERIVATIVE HAVING ANTIVIRAL ACTIVITY ON SARS-CoV-2 | 2022 |
|
RU2820633C1 |
RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
Authors
Dates
2024-06-03—Published
2021-07-15—Filed